Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Date of authorisation: 25/08/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 12, Status: Authorised

Podcast: Inside EMA

Human medicines European public assessment report (EPAR): Epysqli, eculizumab, Date of authorisation: 26/05/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised

Vaccine Monitoring Platform: List of EMA-funded studies

Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 2, Status: Authorised

Trulicity

ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 29 October 2025, 09:30 (CET) to 29 October 2025, 17:00 (CET)